Gyre Therapeutics (GYRE) Work In Process (2022 - 2026)

Gyre Therapeutics (GYRE) has 5 years of Work In Process data on file, last reported at $6.0 million in Q1 2026.

• Quarterly Work In Process rose 74.82% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (up 74.82% YoY) and the FY2025 annual result came in at $6.3 million, up 115.33% from the prior year.
• Work In Process fell to $6.0 million in Q1 2026 per GYRE's latest filing, from $6.3 million in the prior quarter.
• Across five years, Work In Process topped out at $6.3 million in Q4 2025 and bottomed at $2.0 million in Q4 2023.
• The 5-year median for Work In Process is $3.5 million (2024), against an average of $3.8 million.
• The widest annual swing landed in 2023, when Work In Process tumbled 45.54%; it then jumped 115.33% in 2025.
• Tracing GYRE's Work In Process over 5 years: stood at $3.7 million in 2022, then plunged by 45.54% to $2.0 million in 2023, then soared by 46.67% to $2.9 million in 2024, then jumped by 115.33% to $6.3 million in 2025, then declined by 4.98% to $6.0 million in 2026.
• Per Business Quant, the three latest GYRE Work In Process figures stand at $6.0 million (Q1 2026), $6.3 million (Q4 2025), and $4.4 million (Q3 2025).

Peer Comparison